Renaissance Capital logo


Renaissance Capital's August IPO Market Update


Amid the IPO market’s annual August break, five very small issuers raised a combined $42 million, well below the typically-slow month’s 10-year average (10 IPOs, $1.9B). The lineup included four traditional IPOs, all of which finished below issue, and one direct listing, which delivered volatile trading before being halted for insufficient volume. The month’ more

US IPO Weekly Recap: SharkNinja completes listing as wave of small IPOs continues


There were five pricings this past week, four of which are included in our IPO stats. Three issuers submitted initial filings. With the July IPO market behind us, and no notable launches this past week, we likely won't see any major deals until the fall. While more

Budding THC drug developer MIRA Pharmaceuticals prices IPO at $7


MIRA Pharmaceuticals, a preclinical developer of molecular synthetic THC analogs for anxiety and neurologic indications, raised $9 million by offering 1.3 million shares at $7.00, as expected. The company originally filed to offer 1.0 million shares at a range of $6.00 to $8.00, before increasing the proposed share offering and guiding to a $7 anticipated offer price in an more

Cannabis-focused MIRA Pharmaceuticals ups share offering by 20% ahead of $8 million IPO


MIRA Pharmaceuticals, a preclinical biotech developing a molecular synthetic THC analog for anxiety and neuro indications, raised the proposed deal size for its upcoming IPO on Friday. The Baltimore, MD-based company now plans to raise $8 million by offering 1.2 million shares at $7. The company had previously filed to offer 1 million shares at a range of $6 to $8. At the more